AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
6 Phases
Drug Approvals
31
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (2762 trials with phase data)• Click on a phase to view related trials
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab sc Injection in Italy
- Conditions
- Severe Eosinophilic Asthma
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 335
- Registration Number
- NCT07214753
- Locations
- 🇮🇹
AZIENDA ULSS 6 EUGANEA_OSPEDALE DI CITTADELLA U.O.C. di Pneumologia, Cittadella, Padova, Italy
🇮🇹PRESIDIO OSPEDALIERO SANTA MARIA DELLA SPERANZA U.O.C. Medicina Interna, Battipaglia, Salerno, Italy
🇮🇹OSPEDALE MARIA S.S. DELLO SPLENDORE U.O.S.D. Allergologia Territoriale presidio ospedaliero Giulianova, Giulianova, Teramo, Italy
Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT07213076
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Safety Of DAPAGLIFLOZIN (FORXIGA) in Patient With Type 2 Diabetes Mellitus (T2dm) In Vietnam From A Post-Marketing Surveillance Program
- Conditions
- Safety Outcomes
- First Posted Date
- 2025-10-07
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1001
- Registration Number
- NCT07210307
- Locations
- 🇻🇳
HCMC Heart Institute, Ho Chi Minh City, Vietnam
The Eplontersen Pregnancy and Lactation Outcomes Study
- Conditions
- Transthyretin Amyloidosis
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT07205666
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT07205822
- Locations
- 🇪🇸
Research Site, Valencia, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- 667
- Next
News
Arthrosi Raises $153M to Advance Next-Generation Gout Therapy Through Phase III Trials
Arthrosi Therapeutics completed a $153 million Series E funding round led by Prime Eight Capital to advance pozdeutinurad (AR882) through Phase III trials for gout treatment.
Algen Biotechnologies Partners with AstraZeneca in $555M AI-Driven Drug Discovery Deal for Immunology Targets
Algen Biotechnologies announced a multi-target partnership with AstraZeneca worth up to $555 million to accelerate discovery of novel therapeutic targets in immunology using AI-powered drug discovery.
Amgen's Repatha Demonstrates Long-Term Cardiovascular Benefits in Phase III VESALIUS-CV Trial
Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke.
Thermo Fisher Scientific Partners with AstraZeneca BioVentureHub for Collaborative R&D Innovation
Thermo Fisher Scientific's PPD clinical research business has established a new R&D partnership with AstraZeneca BioVentureHub in Gothenburg, Sweden, focusing on collaborative innovation in life sciences.
Aerska Raises $21M to Develop RNA Therapies for Brain Diseases Using Novel Delivery Platform
Irish biotech startup Aerska has secured $21 million in seed funding to develop RNA interference therapies targeting degenerative neurological diseases including Alzheimer's and Parkinson's disease.
Crystalys Therapeutics Emerges with $205M Series A to Advance Gout Treatment Dotinurad
Crystalys Therapeutics launched with $205 million in Series A funding to develop dotinurad, a URAT1 blocker for gout treatment that is already approved in Japan, China, Philippines, and Thailand.
Novartis Launches Direct-to-Patient Platform for Cosentyx with 55% Discount in US
Novartis will launch a direct-to-patient platform on November 1, 2025, offering Cosentyx at a 55% discount off list price to cash-paying patients in the US.
Combination Inhaler Reduces Asthma Attacks in Children by 45% in Landmark Trial
A randomized controlled trial of 360 children aged 5-15 found that a budesonide-formoterol combination inhaler reduced asthma attacks by 45% compared to standard salbutamol treatment.
Factor Bioscience Sues AstraZeneca and Cellectis Over Gene-Editing Patent Infringement
Factor Bioscience filed a patent lawsuit against Cellectis and AstraZeneca in Delaware federal court, alleging infringement of three foundational gene-editing patents related to mRNA TALEN technology.
AstraZeneca Launches Direct-to-Consumer Platform with Up to 70% Drug Discounts Following Trump Administration Pressure
AstraZeneca announced it will offer its diabetes drug Farxiga and asthma drug Airsupra at discounts of up to 70% through a new direct-to-consumer platform launching October 1, 2025.